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1063-62 Safety of Bivalirudin as a Single Antithrombotic Agent 
in Patients Undergoing Percutaneous Coronary 
Intervention and Vascular Brachytherapy With Gamma 
and Beta Emitters
Roswitha Wolfram, Pramod K. Kuchulakanti, Seung-Woon Rha, Rebecca Torguson, 
Donna Whitman, Ellen Pinnow, Karin Nealon, Augusto Pichard, Lowell Satler, Kenneth 
Kent, Joseph Lindsay, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Bivalirudin (Angiomax) has proven to be a valuable alternative to heparin
in percutaneous coronary intervention (PCI). The aim of this study is to assess the effi-
cacy and clinical safety of bivalirudin administration in patients undergoing PCI and vas-
cular brachytherapy (VBT) with γ and β radiation.
Methods: A total of 100 patients who were included in the BRAVES (Brachytherapy and
Bivalirudin Evaluation Study) trial at the Washington Hospital Center, and who underwent
PCI and VBT with either γ (192 Ir) or β (32P or 90Sr/Y) radiation were investigated for pro-
cedural, in-hospital and 30-day clinical outcomes. All patients were treated with bivaliru-
din as a single antithrombotic agent during PCI.
Results: Baseline clinical and angiographic characteristics were similar between the two
groups. In-hospital events showed a higher prevalence of early thrombotic occlusions in
patients treated with γ radiation (25% vs.1.1%, p = 0.02) Thirty-day outcomes were com-
parable in both groups.
Conclusions: The use of bivalirudin as an antithrombotic agent during PCI and vascular
brachytherapy was safe only with β radiation, and should not be use be used in the set-
ting of PCI and γ radiation due to high incidence of intracoronary thrombosis. 
1063-63 Relationship of Troponin I Elevation After 
Uncomplicated Coronary Stenting With Thrombotic (D-
Dimer), Inflammatory (C-Reactive Protein and 
Fibrinogen), Procedural, and Clinical Factors
Jose M. De la Torre-Hernandez, Susana Gonzalez-Enriquez, Fermin Sainz-Laso, Jose M 
Cuesta, Alvaro Figueroa, Javier Zueco, Thierry Colman, Hospital Marques de Valdecilla, 
Santander, Spain
Background: There is significant controversy regarding troponin release after non-compli-
cated percutaneous coronary interventions (PCI) with stent. Pathogenic mechanisms
and predictive factors are not well characterized. We examined the relationship of this
phenomenon with clinical, procedural, thrombotic and inflammatory factors.
Methods:We prospectively studied patients undergoing PCI with stent excluding those
with recent myocardial infarction (<14 days). Levels of C-Reactive Protein (CRP), Fibrino-
gen (F), Fibrin D-dimer (DD), Troponin I (TnI) and CK-MB were determined pre-PCI and
8 and 24 hrs post-PCI.
Results: A total of 221 patients were included with 200 (90.5%) not presenting any peri-
procedural complication. Among the 200 non-complicated cases, 30 patients (15%)
showed TnI elevation after PCI. We compared these 30 cases (group TnI+) with the
remaining 170 without TnI elevation (group TnI-). Patients in group TnI+ were signifi-
cantly older (69±8yrs vs 61±12yrs; P<0.05), had more diffuse lesions (60% vs 22%;
P<0.05) and more lesions treated (1.85 ± 0.7 vs 1.45 ± 0.7; P<0.05). Basal and post-PCI
levels of CRP and DD were significantly higher in group TnI+. Post-PCI increase in DD
was significantly higher in TnI+ group (median 110mgr/ml vs 23mgr/ml; P<0.05). Logistic
regression analysis showed as independent predictors for TnI increase the treatment of
diffuse lesions, age >65 yrs, 2 or more lesions treated and a basal CRP>III cuartile. A
strongly independent association was found between TnI increase and the post-PCI DD
measurement (OR: 13; 95% CI, 4.4 to 37; P= 0.0001). The non-complicated group pre-
sented major cardiac events in 26 pts (13%) in a follow up of 11± 2 months. Only age >65
yrs, diabetes and treatment of diffuse lesions were independent predictors for events.
Conclusions: 1) These findings suggests microthrombosis-embolization as the main
mechanism for TnI elevation in non-complicated PCI. 2)This event was related with age
over 65 years, treatment of multiple and diffuse lesions and high basal CRP levels. 3)
The prognostic significance found in other studies may be explained by the association of
this phenomenon with a more diffuse and aggressive disease.
1063-64 Predilatation Before Distal Protection Device Placement 
Is Associated With Increased Procedure-Related 
Myocardial Infarction: Analysis From the FIRE Trial
Giora Weisz, Campbell Rogers, James Herrmiller, Robert Feldman, Patrick Hall, Robert 
Haber, Zaki Masud, Patrick Cambier, Ronald P. Caputo, Mark Turco, Richard Kovach, 
Bruce Brodie, Howard C. Herrmann, David A. Cox, Roxana Mehran, Gregg W. Stone, 
Cardiovascular Research Foundation, New York, NY
Background: Distal protection devices (DPD) have been shown to prevent embolization
during saphenous vein graft (SVG) stenting. Although optimal to have DPD deployed dur-
ing all phases of intervention, this may be impossible in cases in which device can’t
cross. We examined whether the need for balloon pre-dilatation (PD) prior to lesion
crossing with the DPD impacts outcomes.
Methods: In FIRE trial, 651 pts with SVG stenting were randomized to DPD with either
the FilterWire EX (FW) or the balloon GuardWire (GW) system. When the operator was
unable to cross lesion with DPD, PD with was allowed. Data regarding PD was available
in 598 pts.
Results: PD prior to DPD placement was required in 41 (6.9%) pts; 31 (10.2%) FW, and
10 (3.4%) GW (p=0.001). Compared to pts without PD, PD pts had smaller minimal lumi-
nal diameter (0.79 vs 1.1, p=0.01), higher diameter stenosis (71% vs 66%, p=0.01), and
lower % of pts with baseline TIMI 3 flow (64% vs 84%, p<0.01). After PD, subsequent
attempts to re-introduce the DPD were successful in 24 of 31 FW pts and 10 of 10 GW
(77% vs 100%, p=0.1). Procedural and 30 day outcomes appear in the Table.
Conclusions: Lesions which cannot be crossed by DPD without PD are more complex.
The necessity for PD is associated with increased rates of Q-wave MI and a trend toward
increased MACE. These data emphasize the importance of establishing distal protection
in SVGs before any intervention, and suggest that newer lower profile, more flexible and
crossable devices may further improve the safety of intervention in SVGs.
1063-65 Coronary Blood Flow Velocity and Myocardial Perfusion 
With Balloon Occlusion and Filter-Based Distal 
Protection Devices in Saphenous Vein Graft Stenting: 
Early Experience of Two Centers
Giora Weisz, Amir Halkin, Costantino O. Costantini, Iassan Michev, Arlene Reyes, Issam 
Moussa, Zoran Lasic, Tudor Vagaonescu, Vladimir Ilic, Martin B. Leon, Antonio Colombo, 
Jeffrey W. Moses, Lenox Hill Heart and Vascular Institute, and Cardiovascular Research 
Foundation, New York, NY, Center Cuore Columbus, Milan, Italy
Background: Distal emboli following saphenous vein grafts (SVG) stenting results in
high rates of peri-procedural events. Distal protection devices (DPD) were shown to be
associated with improvement in outcomes. We compared the effect of balloon vs. filter
devices on blood flow (frame count) and myocardial perfusion (blush).
Methods: In two institutions, the first 57 consecutive pts that had filter- DPD SVG-stent-
ing of de-novo lesions were compared to 57 consecutive pts in whom balloon - DPD was
used, in the same period of time. Measurements were done before placement of the
DPD, and post retrieval. Cinangiographic frames were counted from ostium of graft to dis-
tal anastomosis (TFCg), anastomosis to a standardized distal landmark (TFCn), and
combined (TFC). Myocardial blush was graded 0-3 using the Zwolle/CRF methodology.
Results: The two groups were balanced in demographics, risk factors, and clinical pre-
sentation. TIMI flows, frame counts, and blush are shown in Table. In-hospital non Q-
wave MI occurred in 5 pts in the filter group, and 1 in the balloon group (p=ns). There
were no Q-wave MIs, urgent revascularizations, or mortality in either group.
Conclusion: This early world experience in SVG’s treatment suggests that balloon
occlusion and aspiration DPD enhance immediate post procedure coronary flow (espe-
cially in the native coronary segment) and myocardial perfusion compared to filter-based
DPDs. Whether this is due to learning curve with filters, or has clinical relevance
deserves further study.
Parameter Beta Raditaion
(n = 92 patients, 
98 lesions)
Gamma 
Radiation
(n = 8 patients, 8 
lesions)
P 
valu
e
In-hospital TVR-MACE % (Death, Q-wave 
MI,TVR)
0.0 0.0 -
Intracoronary thrombosis, % 1.1 25.0 0.02
Clinical outcome at 30 days:
Death,%
0.0 0.0 -
Q-wave MI, % 0.0 0.0 -
Target Lesion Revascularization, % 3.1 0.0 0.62
Target Vessel Revascularization, % 4.1 0.0 0.56
Combined in- hospital and 30-day 
intracoronary thrombosis, %
3.3 25 0.05
TLR MACE,% 3.3 0.0 0.60
Pre-dilatation No Pre-dilatation p value
n=41 n=557
Procedure
Procedure duration (mins) 66 53 0.0003
Abrupt closure/No reflow/ Distal Emboli 5.1% 4.7% 0.70
Final TIMI 3 flow 95% 97% 0.27
30-day Events 
Death 0 0.7% 1.00
MI 14.6% 8.4% 0.16
Q-wave MI 4.9% 0.5% 0.04
Non Q-wave MI 9.8% 7.9% 0.56
TVR 0 1.4% 1.00
MACE 14.6% 9.2% 0.27
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1063-66 Arterial Closure Device Decreases Vascular 
Complications After Percutaneous Coronary 
Interventions
Michael C. Kim, Annapoorna S. Kini, Paul C. Lee, Marybeth Duffy, Thomas Joseph, 
Warren Sherman, Samin K. Sharma, Mount Sinai School of Medicine, New York, NY
Background: Vascular complication is an important determinant of patient satisfaction
after Percutaneous Coronary Interevntion (PCI). Many studies have shown that use of
closure devices (CD) had lower vascular complications after PCI , but some studies have
not.
Methods: We analyzed patients who had PCI from July 1999 to March 2003: 2,033
patients had attempted closure devices (61% Perclose, 27% Angioseal, 6% Vasoseal,
3% Duett, 2% unsuccessful), and 4,419 patients had manual compression.
Results: Using intention to treat analysis, the use of closure device compared to manual
compression (MC) resulted in decrease in overall vascular complication (1.4% vs. 2.6%,
p=0.0008): specifically, in moderate to large hematomas, or retroperitoneal bleeding
(p=0.0062), pseudoaneurysm (p=0.003), but not in vascular surgery (p=0.7)). Successful
deployment of the device had a very low vascular complication rate (1.2%). The predic-
tors for CD deployment failure(2% of all devices used) were: Month of July (8.4% vs.
1.7% p<0.0001) and increasing body weight (p=0.03). After successful deployment of
CD, the predictors for significant vascular complications included July month, the use of
Duett or Vasoseal (7.7% vs. 1.1% in Perclose or Angioseal, p<0.0001), female sex (2.2%
vs. 0.8%, p<0.0001), CHF NYHA class (p=0.0034), age (p<0.001), and the use of post-
procedural heparin (3.4% vs. 1.1% p=0.04), but not the use of glycoprotein IIb/IIIa
(p=0.8). Weight and ACTmax were not predictors for vascular complication after suc-
cessful deployment of device. If the device fails to deploy, the risk of vascular complica-
tion was much higher (18% vs. 1.2%, p<0.0001), especially if glycoprotein IIb/IIIa had
been used (21% vs. 0%, p=0.04), mostly moderate or large hematoma. Vascular compli-
cation was a significant predictor for in-hospital death (p<0.0001), though the successful
or unsuccessful use of CD had no significant statistical impact on survival. Length of stay
was significantly lower in CD (1.9±3.1 day vs. 2.6±5.0 days) p<0.0001).
Conclusion: Use of vascular closure devices after PCI resulted in significantly lower vas-
cular complications and a significantly lower length of stay.
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Restenosis: Basic Research I
Monday, March 08, 2004, 9:15 a.m.-10:30 a.m.
Morial Convention Center, Hall E-2
9:15 a.m.
803-1 The Number and Adhesive Properties of Circulating 
Endothelial Progenitor Cells in Patients With In-Stent 
Restenosis
Hylton I. Miller, Jacob George, Itzhak Herz, Emil Goldstein, Solicu Abshizada, Arik 
Finkelstein, Yoav Michowitz, Gad Keren, Tel-Aviv Medical Center, Tel-Aviv, Israel
Background: Endothelialization is essential to facilitate vessel healing after stent deploy-
ment to prevent restenosis. Circulating endothelial progenitor cells (EPC) are present in
the peripheral blood and display endothelial functional properties along with ability to
home to damaged vasculature. Prolific in-stent intimal growth may be related to impaired
endothelialization resulting from a reduced number or dysfunction of circulating EPC.
Methods: 27 patients (pts) after stent deployment had recurrent unstable angina and
underwent coronary angiography. In 16 pts in-stent restenosis was demonstrated (group
A), in 6 focal and in 10 diffuse. 11 had patent stents (group B). Both groups were similar
with respect to drug usage and risk factors. Circulating EPC numbers were determined
by the colony-forming unit assay and their phenotype was characterized by endothelial-
cell markers. Adhesiveness of EPC from both groups to extra-cellular matrix and to
endothelial cells was also assayed.
Results: Pts in both groups with in-stent restenosis and with patent stents displayed a
similar number of circulating EPC (26.5±2.6 vs. 25.3±4.8). Pts with diffuse in-stent rest-
enosis exhibited reduced numbers of EPC (24.0±3.9) as compared with patients with
focal restenosis (30.7±1.7; p<0.05). Fibronectin-binding was compromised in pts in group
A as compared to pts of group B (9.2±2.5 vs. 15.3±3.2 cells/field; p<0.01
Conclusions: Reduced numbers of circulating EPC in pts with diffuse in-stent restenosis
and impaired adhesion of EPC from patients with restenosis provides a potential mecha-
nism mediating the exuberant proliferative process of restenosis. These markers, if fur-
ther validated, could provide means of risk stratifying patients for the likelihood of
developing in-stent restenosis.
9:30 a.m.
803-2 Genetic Predictive Factors for Restenosis After 
Percutaneous Transluminal Coronary Angioplasty
Pascalle S. Monraats, Willem R.P Agema, Aeilko H. Zwinderman, Robbert J. de Winter, 
Rene A. Tio, Pieter A.F.M Doevendans, Harry J.G.M Crijns, Moniek P.M de Maat, Douwe 
E. Atsma, Arnoud van der Laarse, Ernst E. van der Wall, J.Wouter Jukema, Leiden 
University Medical Center, Leiden, The Netherlands
Background: Percutaneous transluminal coronary angioplasty (PTCA) is still limited by
the recurrence of luminal stenosis. The underlying mechanisms are not fully understood.
Stratifying patients at risk based upon clinical factors has proven difficult so far. However
evidence exists that gene polymorphisms may play a role in the restenotic process. The
aim of this study was to evaluate if various gene polymorphisms can predict clinically
important restenosis after PTCAin an unselected patient population and thereby influ-
ence the choice of therapy.
Methods: The GEnetic DEterminants of Restenosis (GENDER) project was a multi-
center prospective cohort study, which included 3,146 patients after successful PTCA.
Patients with acute myocardial infarction (MI) were excluded. Genotyping was performed
for different polymorphisms in several candidate genes.
Results: A total of 3,146 patients (age 62.1±10.7 yrs) were followed for 10±3 months. Of
the patients 2,250 (71.5%) were male, 459 (14.6%) had diabetes and 1,459 (46.4%) had
multivessel disease. The majority was treated for stable angina. Stenting was performed
in 2,340 (74.4%) patients. Target vessel revascularisation (TVR) after the first month of
follow-up by either CABG or PTCA was necessary in 304 patients (9.7%). So far we iden-
tified an association between three polymorphism and TVR. The adrenergic beta-2
receptor and stromal cell derived factor (p=0.022, p=0.038 respectively) were associated
with increased risk of TVR. Small inducible cytokine subfamily A (eotaxin) (p=0.057 )
showed a protective association with TVR.
Conclusion: So far in this unselected large group of patients treated with PTCA, we
already identified three polymorphisms in different candidate genes that were related to
restenosis after PTCA. More genotyping is being performed. Our results can contribute
to the unravelling of the restenotic process and might provide a better risk stratification
and lead to a more tailored therapy for patients with identified increased risk of restenosis
after PTCA.
Balloon Filters p-value
n=57 n=57
TIMI 3 flow
Baseline 82.5% 86.0%
 ns
Final 100% 100%
 ns
Blush 3
Bseline 30.4% 28.6%
 ns
Final 66.1% 46.4% 0.05
TFCg
Baseline 24.1 29.2
 ns
Final 14.3 21.3 <0.01
Change 9.8 7.9
 ns
TFCn
Baseline 17.4 13.0
 ns
Final 10.9 11.5
 ns
Change 6.5 1.5 <0.05
TFC
Baseline 43.5 40.6
 ns
Final 26.0 34.0 0.05
Change 17.4 6.6 <0.05
